University of Chicago

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).

796 total trials 158 currently recruiting 451 completed early-phase tilt top decile by trial count

University of Chicago: 796 sponsored US clinical trials, 158 recruiting.

University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.

Top-decile sponsor footprint

University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

796 total, page 5 of 16

ACTIVE NOT RECRUITING Phase 1

Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

NCT02608385

ACTIVE NOT RECRUITING Phase 2

Pembrolizumab in Treating Patients With Malignant Mesothelioma

NCT02399371

ACTIVE NOT RECRUITING Phase 2

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02122185

ACTIVE NOT RECRUITING NA

Thirty Million Words Home Visiting

NCT02216032

ACTIVE NOT RECRUITING

Vasopressor SAT Study

NCT03182335

ACTIVE NOT RECRUITING

Assessment of Paclitaxel-Induced Neuropathy

NCT01953159

ACTIVE NOT RECRUITING

Immune Resolution After Staphylococcus Aureus Bacteremia

NCT01879761

ACTIVE NOT RECRUITING Phase 2

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01816971

ACTIVE NOT RECRUITING NA

Comprehensive Care Physician: Integrated Inpatient and Outpatient Care for Patients at High Risk of Hospitalization

NCT01929005

ACTIVE NOT RECRUITING NA

The Effects of Vertical Position on Gas Exchange in Patients With Respiratory Failure

NCT01705119

ACTIVE NOT RECRUITING

Outcome of BCF Access in Hemodialysis Patients

NCT01693263

ACTIVE NOT RECRUITING NA

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

NCT01342367

ACTIVE NOT RECRUITING

Use of Ultrasonography to Determine Fluid-responsiveness for Shock in a Population of Intensive Care Unit Patients

NCT01680770

ACTIVE NOT RECRUITING

Genetic Factors in Chronic Sinusitis

NCT00880516

ACTIVE NOT RECRUITING

A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer

NCT00989638

ACTIVE NOT RECRUITING

Evaluation of TEACH (Training Early Achievers for Careers in Health) Research

NCT00204035

ACTIVE NOT RECRUITING NA

Chicago Social Drinking Project

NCT00961792

ACTIVE NOT RECRUITING Phase 1

Allogenic Islet Cell Transplantation

NCT00160732

ACTIVE NOT RECRUITING

Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services

NCT00203970

NOT YET RECRUITING NA

Mobile Health Management of Hypertension

NCT05856955

NOT YET RECRUITING Phase 2

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

NCT07346196

NOT YET RECRUITING NA

Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment

NCT07553234

NOT YET RECRUITING NA

The Effect of Apple Cider Vinegar Supplementation on 24-hour Urine Chemistry in Adults

NCT07389226

NOT YET RECRUITING Phase 4

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

NCT06660862

NOT YET RECRUITING Phase 1

Effects of Stimulant Medications in PTSD

NCT07664631

NOT YET RECRUITING NA

Biasing Food Value Construction

NCT07692945

NOT YET RECRUITING Phase 1

Radiation to Treat Joint Damage Caused by Cancer Immunotherapy

NCT07478679

NOT YET RECRUITING

Collagenase Biobank Study

NCT07211230

NOT YET RECRUITING

The FLOW Registry.

NCT07430423

NOT YET RECRUITING

BRIDGE-US: Bridging Readiness in Deployed Neurotrauma Gaps for Excellence

NCT07636213

NOT YET RECRUITING Phase 1

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

NCT07389239

NOT YET RECRUITING Phase 2

Aripiprazole in Body Focused Repetitive Behaviors

NCT05545891

NOT YET RECRUITING

Outpatient Visits Versus Telehealth for Postoperative Care After Minimally Invasive Gynecologic Surgery

NCT07420114

NOT YET RECRUITING

Can 3D Modeling Enhance Patient Understanding, Education, and Surgical Outcomes in Gender Affirming Peritoneal Vaginoplasty?

NCT07412509

COMPLETED NA

Digital Support for Mental Health Intervention in Patients With Inflammatory Bowel Disease

NCT06575660

COMPLETED NA

Pragmatic Use of PAIN-Advanced Dementia Scale in Emergency Departments

NCT06370572

COMPLETED Early Phase 1

Effects of Drugs on Stress Memories

NCT06471647

COMPLETED NA

Single Port Insufflation RCT

NCT06990750

COMPLETED NA

Localized Body Cooling Technology on Sleep and Metabolism in African, American With Overweight and Obesity

NCT05849181

TERMINATED NA

Evaluating Femoral Traction

NCT06160804

COMPLETED NA

Sleep Extension or Regularity to Reduce Diabetes Risk

NCT06128265

COMPLETED Phase 2

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

NCT05399498

COMPLETED NA

A Mobile Health (mHealth) Strategy for Improving Blood Pressure Control Among Adult Hypertensive African Americans

NCT06078540

COMPLETED Early Phase 1

Prosocial Effects of MDMA

NCT05948683

COMPLETED NA

Parent-to-parent Coaching While Awaiting Hospital Discharge With a Child With a Ventilator

NCT05880953

TERMINATED Phase 4

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

NCT05346653

COMPLETED Phase 2

Caplyta in Borderline Personality Disorder

NCT05356013

COMPLETED NA

Mitigating Post-Op RV Dysfunction After LVAD Implantation

NCT05758194

COMPLETED

Autologous Fat Grafting in Radiated Soft Tissue Reconstruction

NCT05890196

COMPLETED

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

NCT05458258

← Previous Page 5 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 137
Phase 2 156
Phase 3 14
Phase 4 53

What is open in the University of Chicago pipeline

158 recruiting of 796 indexed (20% open); 451 completed (57%).

Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Chicago: open-pipeline peers nationwide

Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of ChicagoDana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of UtahUniversity of Texas Southwestern Medical CenterAcera SurgicalAlign TechnologyAltruBioAlvernia University
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 796 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

What to do with this University of Chicago page

796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.

  • 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.